Core technology across all four projects — from ion mobility MS (MS SPIDOC) to tandem MS (TopSpec) to a breakthrough breath analysis platform (ARIADNE).
FASMATECH EPISTIMONIKI KAI TECHNOLOGIKI ANONYMI ETAIREIA
Greek SME developing advanced mass spectrometry platforms for biological analysis, breath diagnostics, and intact pathogen detection.
Their core work
Fasmatech is a Greek technology SME specializing in advanced mass spectrometry instrumentation and related analytical techniques. They develop and apply mass spectrometry platforms for demanding applications — from profiling intact viruses and bacteria to single-cell proteomics and real-time breath analysis. Their work sits at the intersection of precision instrument engineering and life science applications, providing specialized hardware and method development capabilities to research consortia tackling problems in virology, immunotherapy, and structural biology.
What they specialise in
MS SPIDOC targets protein complex imaging, TopSpec profiles antibodies, and ARIADNE analyzes intact viruses and bacteria — all requiring MS adapted for large biological analytes.
VIRUSCAN project applied nanoelectromechanics, nanooptics, and atomic force microscopy/spectroscopy to virology problems.
ARIADNE (2021-2026), their sole coordinated project and largest grant, develops real-time noninvasive breath analysis — signaling a move toward clinical and point-of-care applications.
How they've shifted over time
Fasmatech's early H2020 work (2016–2018) centered on fundamental physics-oriented instrumentation — nanomechanics, optomechanics, atomic force microscopy, and X-ray free-electron laser sample preparation via ion mobility MS. From 2019 onward, they pivoted decisively toward biological and clinical mass spectrometry: antibody profiling for immunotherapeutics, single-cell proteomics, intact pathogen analysis, and real-time breath diagnostics. The shift is from enabling basic science instrumentation to building application-ready platforms aimed at health and diagnostics markets.
Fasmatech is moving from fundamental research instrumentation toward clinical and diagnostic mass spectrometry platforms, making them an increasingly relevant partner for health-tech and point-of-care projects.
How they like to work
Fasmatech operated as a specialist participant in their first three projects, contributing mass spectrometry expertise to consortia led by others. In 2021 they took the coordinator role on ARIADNE — their largest project by funding — indicating growing confidence and ambition. With 23 unique partners across 7 countries from just 4 projects, they engage with diverse consortia rather than relying on repeat partnerships, suggesting adaptability and a broad collaborative network for an SME of this size.
Fasmatech has built a network of 23 distinct partners across 7 European countries through only 4 projects, reflecting broad reach for a small technology company. Their partnerships span universities and research institutes requiring advanced MS instrumentation.
What sets them apart
Fasmatech occupies a rare niche: a Greek SME that both develops and applies advanced mass spectrometry hardware for biological analysis at the frontier — intact viruses, single-cell proteomics, real-time breath diagnostics. Unlike large instrument manufacturers, they are small and agile enough to embed deeply in research consortia and co-develop bespoke solutions. Their progression from participant to coordinator on a flagship breath analysis project demonstrates they are transitioning from a pure technology supplier to a platform leader with their own product vision.
Highlights from their portfolio
- ARIADNETheir first coordinated project and largest grant (EUR 1.37M), developing a breakthrough real-time breath analysis MS platform — signals their strategic direction toward diagnostics.
- VIRUSCANCombined nanooptics, nanomechanics, and atomic force microscopy for virology — an unusual cross-disciplinary application that showcases Fasmatech's instrumentation versatility.
- TopSpecApplied tandem mass spectrometry to next-generation antibody profiling for immunotherapeutics — directly linking their MS capability to a high-value pharma application.